search
Back to results

Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma (HOPE)

Primary Purpose

Cholangiocarcinoma, Interventional Imaging

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Irreversible electroporation
Sponsored by
Poitiers University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cholangiocarcinoma focused on measuring Cholangiocarcinoma, Irreversible electroporation, Interventional radiology

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18-75 years old
  • Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology
  • Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter
  • World Health Organization Performance Index 0 or 1
  • No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years
  • No prior radiotherapy for cholangiocarcinoma
  • Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT <3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease >50ml/min); bilirubin <3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin >9g/dL, leucocytes >3500/mm3, platelets >75000/mm3, prothrombin rate >70%
  • Signature of the informed consent

Exclusion Criteria:

  • Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data
  • Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study
  • Visceral metastases or peritoneal carcinosis
  • History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer
  • Metal biliary prothesis non extractable
  • Patient with history of epileptic events
  • History of myocard infarction for less than 6 months
  • Unstabilised coronary disease for at least 6 months
  • Cardiac rhythm trouble or QT space above 550ms without treatment
  • Patient eligible to liver transplant
  • Patient naive of chemiotherapy
  • Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces
  • Patient with contra-indication to the use of NanoKnife system
  • History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring
  • Refusal or language or psychic incapacity to sign the informed consent
  • Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits)
  • Concomitant participation to another study
  • Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection.
  • Women at age to procreate and not using effective contraception

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Electrodes

    Arm Description

    Electrodes

    Outcomes

    Primary Outcome Measures

    The success rate of the technique, being the realisation of the irreversible electroporation.
    The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%

    Secondary Outcome Measures

    Full Information

    First Posted
    January 18, 2021
    Last Updated
    July 11, 2022
    Sponsor
    Poitiers University Hospital
    Collaborators
    Sport & Collection 2019
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04717687
    Brief Title
    Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma
    Acronym
    HOPE
    Official Title
    Étude Pilote de l'évaluation de la Technique de l'électroporation irréversible Dans le Cholangiocarcinome Infiltrant périhilaire
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2022
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    No enrollment
    Study Start Date
    May 1, 2021 (Actual)
    Primary Completion Date
    June 1, 2022 (Actual)
    Study Completion Date
    June 1, 2022 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Poitiers University Hospital
    Collaborators
    Sport & Collection 2019

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The aim of the study is to evaluate the feasibility of irreversible electroporation in the treatment of locally advanced cholangiocarcinoma. This technique would allow to treat the unresectable part of the tumor to make it more accessible for a secondary surgery.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Cholangiocarcinoma, Interventional Imaging
    Keywords
    Cholangiocarcinoma, Irreversible electroporation, Interventional radiology

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Electrodes
    Arm Type
    Experimental
    Arm Description
    Electrodes
    Intervention Type
    Procedure
    Intervention Name(s)
    Irreversible electroporation
    Intervention Description
    Device: NanoKnife The aim of the treatment is to surround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
    Primary Outcome Measure Information:
    Title
    The success rate of the technique, being the realisation of the irreversible electroporation.
    Description
    The study will be considered positive if the success rate is above 90% and the complication rate below or equal to 30%
    Time Frame
    At Day 0

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: 18-75 years old Patient with infiltrating cholangiocarcinoma of the gallstone convergence considered as unresectable on the pre-operative imaging data performed during the month preceding inclusion, and in multidisciplinary consultation meeting specialised in digestive oncology Histologically (or cytologically) proven tumor of less than 4 cm of the largest diameter World Health Organization Performance Index 0 or 1 No history of other cancer, except baso-cellular skin carcinoma or epidermoid cervix cancer or any other cancer in complete remission for more than 3 years No prior radiotherapy for cholangiocarcinoma Biological analyses performed during the month preceding inclusion : hepatic enzymes (AST and ALT <3N), preserved renal function (creatinine clearance according to Modification of the Diet in Renal Disease >50ml/min); bilirubin <3N; bile drainage must be correct with a bilirubin below 3N , with or without drainage/prothesis, hemoglobin >9g/dL, leucocytes >3500/mm3, platelets >75000/mm3, prothrombin rate >70% Signature of the informed consent Exclusion Criteria: Cholangiocarcinoma of more than 4cm diameter or resectable according tio the imaging data Severe and/or uncontrolled (cardiac, pulmonary, renal, liver decompensation...) visceral failure, in the 6 months preceding the study Visceral metastases or peritoneal carcinosis History of cancers except if remission for more than 3 years, in-situ cancer, epidermoid or baso-cellular cancer Metal biliary prothesis non extractable Patient with history of epileptic events History of myocard infarction for less than 6 months Unstabilised coronary disease for at least 6 months Cardiac rhythm trouble or QT space above 550ms without treatment Patient eligible to liver transplant Patient naive of chemiotherapy Patient with a pacemaker, an implanted automatic defibrillator or an automatic electronic device or an electronic device with metal pieces Patient with contra-indication to the use of NanoKnife system History of hypersensitivity to gadolinium or to iodized contrast product not allowing a suitable radiologic monitoring Refusal or language or psychic incapacity to sign the informed consent Subject who cannot submit to the constraints of the protocol (subjects for which an MRI or a scan is contra-indicated, claustrophobic subjects, non cooperative or not able to come to the follow-up visits) Concomitant participation to another study Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, adults under legal protection. Women at age to procreate and not using effective contraception

    12. IPD Sharing Statement

    Learn more about this trial

    Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating Perihilar Cholangiocarcinoma

    We'll reach out to this number within 24 hrs